Viriom Expands Global Licensing Agreement With Roche For Innovative...

... a single-dose and repeated oral dosing. Presently VM-1500 offers the potential to be a best in class NNRTI for HIV/AIDS. Milos Petrovic, Head of Roche Representative Office in Russia: "We are satisfied with the results achieved, which very well ...

http://www.biospace.com/news_story.aspx?StoryID=316491&full=1